ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfizer, Washington U To Reposition Drugs

by Lisa M. Jarvis
May 24, 2010 | APPEARED IN VOLUME 88, ISSUE 21

Pfizer will pay Washington University School of Medicine in St. Louis $22.5 million over five years to find new uses for current and old drug candidates. The drugmaker will provide detailed preclinical data on 500 molecules, giving the university a head start in finding potential new indications. As part of the pact, Pfizer’s indications discovery unit will move from the company’s Chesterfield, Mo., site to the Center of Research Technology & Entrepreneurial Exchange, which is adjacent to the medical school. The deal expands on a decades-long research relationship between Pfizer and the university.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment